Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that the U.S. FDA has completed a ...
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic ...
NEW YORK--(BUSINESS WIRE)--CI&T (NYSE: CINT), a global digital specialist, announces today, as a complement to the market announcement of August 16, 2022, the completion of the acquisition of ...
SUNRISE, Fla., April 28, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, has opened ...
Trelegy Ellipta is a maintenance treatment for patients with asthma and COPD. "The FDA's acceptance of our ANDA filing for the substitutable generic version of high-strength Trelegy Ellipta is another ...
SUNRISE, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., a U.S. based, clinical-stage, revenue-generating biopharmaceutical company focused on developing inhaled therapeutics for ...
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results